Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic Acid for COVID-19 Prevention
NCT05659654Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ursodeoxycholic acid in coronavirus disease 2019 (COVID-19), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Dec 2022; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05659654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659654.